Is Airduo a steroid-only inhaler or a combo?

What are the active ingredients in Airduo?

Airduo is a combination inhaler that contains the long-acting muscarinic antagonist (LAMA) Umeclidinium, and the inhaled corticosteroid (ICS) Fluticasone Furoate [1]. Umeclidinium works by relaxing the airway muscles to improve breathing, while Fluticasone Furoate reduces inflammation and swelling in the airways.

How does Airduo compare to other combination inhalers?

Compared to other combination inhalers, Airduo contains a unique combination of a LAMA and an ICS. Other inhalers may contain a combination of a long-acting beta-agonist (LABA) and an ICS, such as Symbicort, which contains Budesonide and Formoterol [2].

Are there any biosimilars available for the ICS component of Airduo?

Yes, there are biosimilars available for Fluticasone Furoate, but none have been approved for the combination product Airduo. However, a biosimilar of Fluticasone Furoate has been approved in the UK, under the name Fosten [3].

When does the patent for Airduo expire?

The patent for Airduo is expected to expire in 2026, according to data from DrugPatentWatch.com [4]. However, it's worth noting that patent expirations can be extended or terminated, and the actual expiration date may be different.

References:

[1] GlaxoSmithKline. (n.d.). Airduo Digihaler. Retrieved from https://www.gsk.com/en-gb/products/airduo-digihaler/

[2] AstraZeneca. (n.d.). Symbicort. Retrieved from https://www.astrazeneca.com/our-work/our-portfolio/symbicort.html

[3] Medicines and Healthcare products Regulatory Agency. (n.d.). Fosten. Retrieved from https://www.mhra.gov.uk/licensing/pharmaceuticals/medicines-products/fosten/

[4] DrugPatentWatch.com. (n.d.). Airduo. Retrieved from https://www.drugpatentwatch.com/brand/airduo